- Home
- QNCX vs BANX Comparison
QNCX vs BANX Comparison
Compare QNCX & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QNCX | BANX |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 172.0M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | QNCX | BANX |
|---|---|---|
| Price | $3.06 | $20.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 979.1K | 23.4K |
| Earning Date | 11-12-2025 | 06-17-2025 |
| Dividend Yield | N/A | ★ 9.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | N/A | ★ $29,467,794.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.88 |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $0.72 | $17.99 |
| 52 Week High | $4.55 | $21.67 |
Technical Indicators
Market Signals| Indicator | QNCX | BANX |
|---|---|---|
| Relative Strength Index (RSI) | 47.31 | 35.20 |
| Support Level | $2.85 | $21.20 |
| Resistance Level | $3.72 | $21.79 |
| Average True Range (ATR) | 0.31 | 0.38 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 41.38 | 18.01 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.